Journal Article

CMV Viremia Is Associated With Poor Fungal Clearance From Cerebrospinal Fluid in Adult Patients With HIV-Associated Cryptococcal Meningitis

Open Forum Infectious Diseases, Volume 13, Issue 11, November 2026, ofag668, https://doi.org/10.1093/ofid/ofag668
Published:
12 October 2026
Article history
Received:
23 May 2026
Accepted:
02 October 2026
Published:
12 October 2026
Corrected and typeset:
18 November 2026

Abstract

Background

Cryptococcosis remains a leading cause of HIV-associated mortality globally. Cytomegalovirus (CMV) viremia is common in advanced HIV disease and is associated with excess mortality through unclear mechanisms. We assessed if CMV viremia is associated with slower rates of Cryptococcus clearance from cerebrospinal fluid (CSF) in persons being treated for HIV-associated cryptococcal meningitis.

Methods

We quantified baseline CMV DNA using PCR from cryopreserved plasma in adults with cryptococcal meningitis in Uganda from 2010 to 2024. The early fungicidal activity (EFA) was calculated as the negative slope of log10  Cryptococcus colony-forming units (CFU)/mL CSF/day over 18 days. We compared fungal burden, EFA, proportions achieving CSF sterility, and 18-week mortality by CMV status.

Results

Among 508 participants, 37% had detectable CMV viremia. Median EFA was lower in those with CMV viremia (0.31 vs 0.35 log10 CFU/mL/day; P = .03), with a greater proportion having EFA < 0.20 CFU/mL/day (30.5% vs 22.4%; P = .04) and with fewer achieving CSF sterility by day 18 (36% vs 54%; P < .001) than those without CMV viremia. Mortality at 18 weeks was higher in CMV viremic participants (43% vs 26%; P < .001). Participants with both CMV viremia and EFA < 0.20 had 2.5-fold increased hazard of death compared with those without CMV viremia and with EFA ≥ 0.20 (adjusted hazard ratio = 2.48 [95% CI, 1.52–4.06]). No interaction with antifungal treatment was observed.

Conclusions

Cytomegalovirus viremia is associated with impaired CSF fungal clearance and increased mortality in HIV-associated cryptococcal meningitis—potentially supporting an immunomodulatory role. Further investigation into the underlying immune response in HIV-CMV co-infection is warranted.

Central nervous system infection due to Cryptococcus is the most common cause of HIV-associated meningitis in Uganda and remains a significant source of morbidity and mortality worldwide in persons with advanced HIV disease [1–3]. Despite important advances in optimizing antifungal regimens, mortality at 10 weeks still exceeds 20% in low- and middle-income countries (LMIC). One predictor of mortality in HIV-associated cryptococcal meningitis is the rate of fungal clearance from the cerebrospinal fluid (CSF), termed early fungicidal activity (EFA). Early fungicidal activity is calculated by determining the change in log10  Cryptococcus colony-forming units (CFU) per mL of CSF per day of therapy. We have previously shown that CSF fungal clearance slower than 0.20 log10 CFU/mL/day is associated with increased risk for mortality [4]. Given the association with mortality, there is a need to investigate factors affecting EFA beyond antifungal regimen.

Persons with advanced HIV disease are additionally at risk for complications from reactivation of latent Herpesviridae, such as cytomegalovirus (CMV), Ebstein–Barr virus (EBV), herpes simplex virus, and varicella zoster virus. Cytomegalovirus seroprevalence is nearly universal in adults living with HIV in LMIC settings, putting this population at risk for CMV reactivation as CD4+ T-cell counts decrease [5]. We have demonstrated baseline prevalence rates of active CMV viremia between 36% and 52% in Ugandans with HIV-associated cryptococcal meningitis. These studies demonstrated ∼1.6–3.2-fold greater hazard of death in persons with any baseline CMV viremia compared to those without detectable CMV viremia [5, 6]. In cohorts across multiple countries, the risk of mortality increases with higher CMV viral loads ≥ 1000 IU/mL [7, 8]. However, an important unresolved knowledge gap is whether CMV viremia is driving the observed mortality trend or is instead a biomarker of profound immune dysfunction in persons with advanced HIV disease [9].

Investigations into mechanisms of deleterious effects associated with CMV in persons with HIV-associated cryptococcal meningitis are warranted. Cytomegalovirus viremia has been associated with increased rates of fungal infections in kidney transplant recipients [10], hematopoietic stem cell transplant [11], and immunosuppressed patients with rheumatologic disease [12]. Further, a randomized clinical trial of prophylactic high-dose valacyclovir versus placebo in kidney transplant recipients demonstrated significantly fewer fungal and bacterial infections in the valacyclovir group [13]—suggesting a causal effect. Thus, we hypothesized that active CMV replication (ie, viremia) might impact the clinical course of cryptococcal meningitis through modulation of host–pathogen interactions leading to enhanced fungal pathogenesis. While an extensive immunological investigation is beyond the scope of this manuscript, CMV has the well-described ability to confer immunomodulatory functions on the infected host. The specific goal of this manuscript is to investigate if CMV viremia is associated with impaired CSF clearance of Cryptococcus, which is a known risk factor for mortality [4], and may represent an end result of host immunomodulation.

METHODS

Study Population and Setting

From 2010 to 2024, we prospectively enrolled adults (≥18 years) with HIV-1 and associated cryptococcal meningitis from 3 tertiary referral hospitals in Uganda: Mulago National Referral Hospital and Kiruddu National Referral Hospital in Kampala and Mbarara Regional Referral Hospital in Mbarara, Uganda. Diagnosis was made by CSF cryptococcal antigen (IMMY, Norman, Oklahoma) [14]. A fungal culture was sent from each lumbar puncture, and Cryptococcus was quantified in CFUs using established protocols [15]. Participants received amphotericin-based induction therapy for treatment of cryptococcal meningitis with standardized supportive care including electrolyte monitoring/replacement and therapeutic lumbar punctures to control elevated intracranial pressure as needed. Participants included in this analysis were enrolled into a mix of observational and randomized controlled trials including: testing ART timing [16], testing adjunctive sertraline [17], testing oral amphotericin [18], as well as observational cohorts [19, 20]. Induction therapy changed over time as international standards were updated, initially consisting of amphotericin B plus fluconazole-based regimens, before transitioning to amphotericin B plus flucytosine-based regimens in 2019.

DNA Extraction and Polymerase Chain Reaction (PCR)

We quantified CMV DNA concentrations from cryopreserved samples from all study participants with plasma available for testing. Cryopreserved samples were shipped to the University of Minnesota where CMV DNA quantification was performed. We performed DNA extraction from 200 µL of plasma or serum using the QIAcube HT (QIAGEN, Hilden, Germany) and QIAamp 96 Virus DNA QIAcube kit according to the manufacturer's instructions. Multiplex qPCR was performed using the LightCycler 480 System (Roche, Basel, Switzerland) and UL83 targeted primers [21]. Detailed PCR methods can be found in the Supplementary Methods section. Laboratory staff processed de-identified samples and were blinded to participant data and outcome. Cytomegalovirus DNA quantification in copies/mL values were converted to international units (IU)/mL using the WHO International Standard for Human Cytomegalovirus for Nucleic Acid Amplification Techniques (NIBSC code 09/162) as controls for CMV viral load [22].

Statistical Analysis

We defined CMV viremia as any quantity of CMV DNA in plasma above the threshold of PCR detection, which was 77 IU/mL for our assay [22, 23]. For this study, we considered any sample within 3 days of meningitis diagnosis as a baseline sample. Baseline characteristics were compared by CMV viremia status using χ² or Kruskal–Wallis testing.

The primary outcome in our analysis was EFA, which was calculated as the negative slope change in quantitative CSF fungal burden (log10 CFU/mL) over the first 18 days of therapy, estimated by linear regression of all available measurements within that interval. Participants who did not have at least 2 quantitative culture results available within the first 18 days were excluded as they did not have a calculable EFA. Similarly, participants with sterile CSF (ie, without fungal growth) at baseline were excluded from the primary analysis insofar as they could not contribute to EFA analyses, but these are separately described by CMV status in the supplement (Supplementary Results). We determined the proportion of participants who achieved sterility by day 18 stratified by baseline CMV viremia status. All-cause mortality through 18 weeks was analyzed with survival curves for groups formed by CMV viremia status at baseline and EFA. We reported odds ratios and hazard ratios with 95% confidence intervals (95% CI), and P values for multivariate logistic and Cox regressions, which adjusted for CD4 count, CSF white cell count, baseline CSF fungal burden, and fluconazole backbone versus flucytosine backbone eras of antifungal therapy. All statistical analyses were performed in SAS version 9.4 (SAS Institute, Cary, North Carolina, United States). A P value of ≤.05 was considered statistically significant.

RESULTS

We included a total of 508 participants with cryptococcal meningitis who had both plasma CMV viral load measurement and EFA through 18 days available (Supplementary Figure 1). The cohort had a median age of 35 years (interquartile range [IQR], 30–41) and was comprised of 40% (204/508) women. The majority of participants were ART naïve (69% [352/508]) at time of cryptococcal meningitis diagnosis. Overall, 187 (37%) had any detectable CMV DNA in baseline blood samples, with a median CMV viral load of 418 IU/mL (IQR, 141–3301; max, 902 700). The median CD4 count was 12 cells/μL (IQR, 6–38) for those with CMV viremia versus 19 cells/μL (8–54) for those without CMV viremia (P = .002). Participants with CMV viremia had higher baseline quantitative burdens of Cryptococcus on CSF culture versus participants without CMV viremia (88 000 vs 37 500 CFU/mL CSF; P < .001). Persons with CMV viremia were also more likely to lack CSF pleocytosis with white blood cells ≤ 5 cells/μL and were more likely to have lower hemoglobin levels. Baseline characteristics by any detectable CMV viremia are compared in Table 1.

Table 1.

Baseline Characteristics by CMV Viremia Status

Baseline CharacteristicCMV Viremia PresentCMV Viremia AbsentP Value
N per group187321
Women83 (44%)121 (38%).14
Age, years35 [30, 40]35 [30, 41].87
Blood CD4+ T cells/µL12 [6, 38]19 [8, 54].002
 CD4 < 50 cells/µL142 (81%)218 (73%).06
 CD4 unknown12 (6%)24 (8%)−-
Receiving HIV therapy52 (28%)104 (32%).28
 Months on ART2.3 [0.6, 24]4.0 [0.9, 19].54
CMV DNA, IU/mL418 [141, 3301]−-−-
Glasgow Coma Scale score < 1559 (32%)95 (30%).64
Hemoglobin, g/dL11.3 [9.8, 12.6]11.9 [10.4, 13.2].002
CSF white cells ≤ 5 cells/µL132 (72%)163 (52%)<.001
CSF opening pressure, mmH2O270 [180, 380]260 [160, 380].41
CSF quantitative culture, Cryptococcus CFU/mL CSF88 000 [10 400, 380 000]37 500 [1 800, 221 000]<.001

Data are N (%) or median [interquartile range]. P values are χ² or Kruskal–Wallis testing.

Abbreviations: CMV, cytomegalovirus; ART, antiretroviral therapy; IU/mL, international units per milliliter; CSF, cerebrospinal fluid; TB, tuberculous.

We compared EFA through 18 days and the proportion achieving sterility through 18 days for persons with CMV viremia versus those without CMV viremia. The median EFA was 0.31 log10 CFU/mL/day (IQR, 0.17–0.44) in the CMV viremia group and 0.35 log10 CFU/mL/day (IQR, 0.22–0.51) in the no CMV viremia group (Table 2; Supplementary Figure 2). Cerebrospinal fluid culture sterility was achieved by 18 days in 36% of CMV viremic persons compared to 54% of CMV non-CMV viremic persons (P < .001). When we categorized participants by the clinically meaningful cutoff of EFA < 0.20 log10 CFU/mL/day, we found that 31% of those with CMV viremia had EFA < 0.20 log10 CFU/mL/day versus 22% of those without CMV viremia (P = .04). We noted that those with the highest CMV viral load tertile had the largest proportion (35.5%) of participants with EFA < 0.20 log10 CFU/mL/day, although the median EFA in this group was somewhat higher than the lowest tertile (Supplementary Table 1). Among those with an EFA ≥ 0.20, only 51% (66/130) of participants with CMV viremia achieved sterility compared with 67% (167/249) without CMV viremia (P = .002) (Supplementary Table 2). Of those with EFA < 0.20, 4% (2/57) of those with CMV viremia and 10% (7/72) of those without CMV viremia achieved sterility (P = .17). After adjustment for CD4 count, CSF white cell count, baseline CSF fungal burden, and antifungal era, CMV viremia remained significantly associated with failure to sterilize CSF by 18 days (aOR = 1.56; 95% CI, 1.03–2.35; P = .03) while trending strongly toward increased odds of EFA < 0.20 log10 CFU/mL/day (aOR = 1.52; 95% CI, .97–2.40; P = .07) (Table 3).

Table 2.

Key Outcomes by CMV Viremia Status

OutcomeCMV Viremia Present (N = 187)CMV Viremia Absent (N = 321)P Value
EFA, log10 CFU/mL/d
 Mean (95% CI)0.37 (0.30, 0.43)0.43 (0.39, 0.48).11
 Median (IQR)0.31 [0.17, 0.44]0.35 [0.22, 0.51].03
EFA < 0.20 log10 CFU/mL/d57 (31%)72 (22%).04
CSF sterile by day 1868 (36%)174 (54%)<.001
Death by week 1880 (43%)83 (26%)<.001
Death by day 3047 (25%)52 (16%).01

Values are mean (95% CI), median [IQR], or N (%). Early fungicidal activity calculated using all cultures through 18 d. P values are via χ², Kruskal–Wallis, or Linear Regression, as appropriate.

Abbreviations: EFA, early fungicidal activity; CFU, colony-forming units; 95% CI, 95% confidence interval; IQR, interquartile range; CSF, cerebrospinal fluid.

Table 3.

Multivariable Logistic Regression for Predictors of Poor Fungal Clearance

OutcomePredictorsOdds Ratio (95% CI)P Value
EFA < 0.20, log10 CFU/mL/d
CMV detectable1.52 (.97, 2.40).07
CD4 cell count (per 20 cell increase)0.85 (.75, .97).02
CSF WBC ≤ 5 cells/µL1.25 (.77, 2.02).37
CSF quantitative culture (per log10 CFU)0.75 (.63, .89)<.001
Failure to sterilize CSF by day 18
CMV detectable1.56 (1.03, 2.35).03
CD4 cell count (per 20 cell increase)0.90 (.82, .99).03
CSF WBC ≤ 5 cells/µL1.46 (1.24, 1.70)<.001
CSF quantitative culture (per log10 CFU)1.66 (1.10, 2.51).02

Abbreviations: EFA, early fungicidal activity (log10 CFU/mL/d); CSF, cerebrospinal fluid; WBC, white blood cells; CFU, colony-forming units.

Mortality at 18 weeks was 43% (80/187) in those with CMV viremia versus 26% (83/321) in those without CMV viremia (P < .001; Table 2). The hazard ratio for 18-week mortality for CMV viremic persons was 1.84 (95% CI, 1.35–2.50) compared to non-viremic persons (P = .001). Figure 1 demonstrates survival probability through 18 weeks across dichotomized groups of detectable CMV viremia and an EFA cutoff of 0.20 log10 CFU/mL/day. The most favorable 18-week mortality was seen in the group with no detectable CMV and EFA ≥ 0.20 log10 CFU/mL/day (25% [61/249]). The highest mortality was seen in the group with detectable CMV and EFA < 0.20 log10 CFU/mL/day (47% [27/57]). Participants with CMV viremia and EFA < 0.20 log10 CFU/mL/day had a ∼2.5-fold increased hazard of death compared to those without CMV viremia and EFA ≥ 0.20 (adjusted hazard ratio = 2.48; 95% CI, 1.52–4.06; P < .001), after multivariable adjustment (Table 4).

Figure 1 shows the survival curve across each level for the combined risk factors of CMV viremia present or absent and early fungicidal activity less than or greater than or equal to 0.20 log10 Cryptococcus CFU/mL/day.
Figure 1.

Kaplan–Meier for 18-wk mortality by CMV viremia and EFA groupings. This figure demonstrates survival probability through 18 wk stratified by the categorical presence of CMV viremia (yes/no) and early fungicidal activity (EFA) dichotomized at the clinically meaningful breakpoint of 0.20 log10  Cryptococcus CFU/mL/d. The combined presence of CMV viremia and EFA < 0.20 log10  Cryptococcus CFU/mL/d resulted in the highest mortality rate of 47.4% by 18 wks.

Table 4.

Multivariable Cox Proportional Hazards Models for 18-Week Mortality

Model AModel B
ParameterHazard Ratio (95% CI)P ValueaHazard Ratio (95% CI)P Valueb
No CMV Viremia
EFA ≥ 0.20
REFREF
No CMV Viremia
EFA < 0.20
1.33 (.81, 2.16).261.41 (.83, 2.39).20
Yes CMV Viremia
EFA ≥ 0.20
1.76 (1.22, 2.55).0031.64 (1.11, 2.44).01
Yes CMV Viremia
EFA < 0.20
2.38 (1.51, 3.75)<.0012.48 (1.52, 4.06)<.001
Adjunctive Fluconazole Antifungal erac1.27 (.92, 1.76).141.28 (.90, 1.83).17
CD4 cell count, per 20 cell increase…1.03 (.98, 1.09).26
CSF WBC ≤ 5 cells/µL…1.18 (1.02, 1.35).02
CSF quantitative culture, per log10 CFU increase…1.08 (.75, 1.55).67

Abbreviations: EFA, early fungicidal activity (log10 CFU/mL/d); CSF, cerebrospinal fluid; WBC, white blood cells; CFU, colony-forming units.

aP value includes adjustment for antifungal eras (2010–2017 with fluconazole vs 2021–2024 with flucytosine as reference).

bP value includes adjustment for antifungal eras, CD4 count, CSF white blood cells, and baseline CSF fungal burden.

cP value for interaction effect between CMV and EFA groupings and antifungal era was P > .10. Thus, the interaction effect was not included in the model.

We broadly assessed the effect of changes in antifungal induction therapy (by eras of 2010–2017 vs 2021–2024) on both fungal clearance and mortality. The median EFA was 0.33 log10 CFU/mL/day (IQR, 0.20–0.48) in the earlier adjunctive fluconazole era and 0.31 log10 CFU/mL/day (IQR, 0.21–0.51) in the later adjunctive flucytosine era (P = .98). In the fluconazole era, we found that 50% (149/299) achieve CSF sterility by day 18, compared to 45% (93/209) in the flucytosine era (P = .24). Death by 18 weeks was higher in the fluconazole era at 36% (106/299) versus 27% (57/209) in the later flucytosine era (P = .05). However, after multivariate Cox regression (Table 4), antifungal era was not independently associated with death (adjusted hazard ratio 1.28; 95% CI, .90–1.83; P = .17). We additionally assessed for an interaction effect between CMV viremia and antifungal era on both the impact of EFA and 18-week mortality. The categorical presence of CMV viremia did not interact with antifungal regimens dichotomized by era (adjunctive fluconazole vs flucytosine) when analyzed by linear regression (P = .98). Similarly, no interaction was seen in the 18-week survival Cox model for CMV viremia and antifungal era (P = .25).

DISCUSSION

We hypothesized that CMV viremia at time of cryptococcal meningitis diagnosis may be associated with slower clearance of Cryptococcus from the CSF—consistent with the idea that CMV might drive increased mortality in persons with HIV-associated cryptococcal meningitis via indirect immune effects. Our study demonstrates several components of evidence supporting this hypothesis. Persons with CMV viremia had higher quantitative counts of fungal colonies on culture at baseline, had slower clearance of yeast from the CSF as measured by median EFA, and were less likely to achieve sterile cultures by the end of antifungal induction therapy. Thus, multiple different measures of ability to clear Cryptococcus appear impaired in persons with detectable CMV viremia.

Interestingly, the effect of CMV on achieving sterility was more pronounced in those with EFA >0.20 log10 CFU/mL/day, where the absolute difference was 16% lower in those with CMV viremia, compared with an absolute 6% reduction in the EFA < 0.20 group. This is likely due to the low overall rates of achieving sterility in those with EFA < 0.20 log10 CFU/mL/day, consistent with a demonstrated inability to clear yeast adequately from the CSF. The overall effect was clear however, with an absolute difference of 18% lower in those with CMV viremia compared to those without.

Multivariable modeling demonstrated that several factors are contributing to poor fungal clearance. Unsurprisingly, baseline CD4 count, lack of CSF pleocytosis, and higher initial fungal burden were all independently associated with failure to achieve sterility by day 18 after meningitis diagnosis. Despite these influences, CMV remained significantly associated with 1.5-fold greater odds of failing to achieve CSF sterility (aOR = 1.56; 95% CI, 1.03–2.35; P = .03). When predicting those with EFA < 0.2 log10 CFU/mL/day, CMV viremia trended similarly but no longer maintained significance (aOR = 1.52; 95% CI, .97–2.40; P = .07), while CD4 count and CSF quantitative culture did remain significant. Of note, a higher CSF quantitative culture having a protective association against poor EFA likely in-part reflects a mathematical artifact whereby persons with high initial fungal burdens have greater slopes for clearance rate available.

Mortality Association

Further, we demonstrated that CMV viremia combines with poor EFA to worsen the association with survival, beyond what poor EFA predicts alone. Our data demonstrated the 2 lowest 18-week mortality rates were in those without CMV viremia (24.5% if EFA ≥ 0.20; 30.6% if EFA <0.20 log10 CFU/mL/day), while the 2 highest mortality rates were seen in those with CMV viremia (40.8% if EFA ≥ 0.20; 47.4% if EFA < 0.20 log10 CFU/mL/day). This trend suggested that CMV may be a stronger risk factor for mortality than EFA. Multivariable Cox regression demonstrated these patterns held true when adjusting for possible confounders, with the CMV viremia and EFA < 0.2 log10 CFU/mL/day group experiencing a 2.48 increased risk for death compared to those without CMV viremia and with EFA ≥ 0.2 log10 CFU/mL/day. Early fungicidal activity values < 0.20 log10 CFU/mL/day have traditionally been associated with suboptimal monotherapy fluconazole-based antifungal regimens for cryptococcal meningitis [4]; however, a proportion of persons receiving standard first-line amphotericin induction therapy still have poor EFA, and thus this finding remains clinically relevant.

Cytomegalovirus viremia has been consistently shown to be associated with poor outcomes in HIV disease [24–27] and specifically in HIV-associated cryptococcal meningitis [5, 6, 8]. However, it remains unclear whether CMV is driving detrimental outcomes, or whether it is simply a sensitive marker of severe immune dysfunction. We have previously hypothesized that deleterious modulation of the host's immune system may impair Th1-mediated immune protection against intracellular pathogens [9], although host immune system investigations are beyond the scope of this manuscript. Inquiries into the “indirect effects” of CMV infection are an area of active research.

Possible Immunology Mechanisms for Poor Fungal Clearance

Cytomegalovirus reactivation in immunosuppression has previously been linked to invasive fungal disease, primarily in transplant populations. Cytomegalovirus viremia (or the analogous pp65 antigenemia) has specifically been linked to increased risk for invasive fungal infections in hematopoietic stem cell transplantation [11, 28, 29], liver transplant [30, 31], and kidney transplant [10] populations. The association of fungal infections and CMV viremia in populations with HIV are less-well studied. Proposed mechanism by which CMV might impair response to fungal pathogens include downregulation of major histocompatibility complexes on antigen presenting cells [32], modification of macrophage migration and chemotaxis [33], dysregulation of NK cell responses [34], and anti-inflammatory effects of IL-10 upregulation with impairment of IFN-gamma-driven responses [35]. A small, randomized trial of valganciclovir versus placebo in CMV-seropositive participants with chronic HIV infection demonstrated less general CD8+ T-cell activation after 8 weeks of valganciclovir therapy, suggesting CMV suppression led to reversals in immune modulation [36]. While the host–virus interaction with CMV remains complex, evidence suggests that various etiologies of immune modulation might make a person more susceptible to fungal infections.

Strengths and Limitations

One of the strengths of our study was the large number of participants with a known clinical outcome following the diagnosis of cryptococcal meningitis. However, in order to leverage the maximum value of our dataset, we included participants over different eras of antifungal therapy. While our post hoc testing for interactions between CMV viremia and antifungal era failed to reveal any concerning effects on fungal clearance, unmeasured confounding may remain. Multivariate adjusted analyses for outcomes of fungal clearance and mortality have been included, focused on differences between the CMV viremic and non-viremic groups. However, we caution readers that CMV viremia may influence effects through biological processes linking host factors with outcomes. Thus, adjusting for a factor such as CSF white blood cell count may represent an over-adjustment in the model, as this factor might represent a causal pathway mediator rather than an independent confounder. Our prior publications on these individual study datasets have previously addressed comprehensive multivariate survival modeling in HIV-associated meningitis [5, 6]. As participants had to have at least 2 lumbar punctures to have a calculable EFA, there may be systematic differences in populations who did not receive multiple LPs, which may have occurred for reasons such as procedure refusal, failed LP attempts, or early death. Lastly, we did not measure other herpes viruses in this cohort and are thus unable to account for any interactions or additional effect modification that they may have.

CONCLUSIONS

Our study aimed to determine if the presence of detectable CMV viremia at baseline was broadly associated with impaired CSF clearance of Cryptococcus amongst persons with HIV-associated cryptococcal meningitis. We found that CMV viremia was strongly associated with failure to clear Cryptococcus from the CSF by day 18 after completing induction antifungal therapy. Persons with both CMV viremia and EFA < 0.20 log10 CFU/mL/day had a ∼2.5-fold increased hazard of 18-week mortality compared to persons without CMV viremia and with EFA ≥ 0.20 log10 CFU/mL/day. Although the underlying mechanisms are uncertain, our data suggest that CMV viremia may indirectly impair the host's ability to clear intracellular yeast during invasive infection, a finding similar to those observed in immunosuppressed transplant populations. More research is needed to understand the immune response during HIV-CMV co-infection.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. We are appreciative of the study teams and hospital staff working continuously to provide compassionate care to the participants and patients at Mulago National Referral Hospital. IDI Meningitis Study Team: Abdu K. Musubire, Lillian Tugume, Morris Rutakingirwa, Derrick Kasozi, Samuel Jjunju, Jane Gakuru, Sarah Kimuda, Sarah Maria Najjuka, Suzan Namombwe, Enos Kigozi, Faizo Ssekindi, Enock Kagimu, Darlisha A. Williams, Mahsa Abassi, Mable Kabahubya, Richard Kwizera, Samuel Okurut, Suzan Mulwana, Sylvia Namanda, Andrew Akampurira, Tonny Luggya, Michael Okiror, Jane Frances Ndyetukira, Florence Kugonza, Alice Namudde, Carol Namujju, Alisat Sadiq, Shifah Nabbaale, Grace Menya, Asmus Tukundane, Dora Babirye, Wilber Bakka, Eva Laker, Rhona Muyise, John Kisembo, Andrew Luswata, Joseph Owori, Tenywa David, Fred Lyazzi, and Emmanuel Mande.

Ethical approval. The parent trials received institutional review board (IRB) approval from the appropriate US and Ugandan institutions, including the Uganda National Drug Authority and Uganda National Council of Science and Technology. All trial participants provided written informed consent for the storage and future testing of samples for research purposes.

Data availability. The data underlying this article are available through the Harvard Dataverse, found at https://dataverse.harvard.edu/dataverse/meningitis-studies.

Financial support. This research was made possible by the National Institutes of Health’s National Institute of Neurologic Disorders and Stroke (K23NS137968, R01NS086312); the National Center for Advancing Translational Sciences (KL2TR002492); the National Institute of Allergy and Infectious Diseases (U01AI089244; K24AI184270); Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD099866); and the Fogarty International Center (D43TW009345).

References

1

Rajasingham
 
R
,
Smith
 
RM
,
Park
 
BJ
, et al.  
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
.
Lancet Infect Dis
 
2017
;
17
:
873
–
81
.

2

Ellis
 
J
,
Bangdiwala
 
AS
,
Cresswell
 
FV
, et al.  
The changing epidemiology of HIV-associated adult meningitis, Uganda 2015–2017
.
Open Forum Infect Dis
 
2019
;
6
:ofz419.

3

Tenforde
 
MW
,
Gertz
 
AM
,
Lawrence
 
DS
, et al.  
Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis
.
J Int AIDS Soc
 
2020
;
23
:e25416.

4

Pullen
 
MF
,
Hullsiek
 
KH
,
Rhein
 
J
, et al.  
Cerebrospinal fluid early fungicidal activity as a surrogate endpoint for cryptococcal meningitis survival in clinical trials
.
Clin Infect Dis
 
2020
;
71
:
e45
–
9
.

5

Skipper
 
C
,
Schleiss
 
MR
,
Bangdiwala
 
AS
, et al.  
Cytomegalovirus viremia associated with increased mortality in cryptococcal meningitis in sub-Saharan Africa
.
Clin Infect Dis
 
2020
;
71
:
525
–
31
.

6

Skipper
 
CP
,
Hullsiek
 
KH
,
Cresswell
 
FV
, et al.  
Cytomegalovirus viremia as a risk factor for mortality in HIV-associated cryptococcal and tuberculous meningitis
.
Int J Infect Dis
 
2022
;
122
:
785
–
92
.

7

Jarvis
 
JN
,
Lawrence
 
DS
,
Meya
 
DB
, et al.  
Single-dose liposomal amphotericin B treatment for cryptococcal meningitis
.
N Engl J Med
 
2022
;
386
:
1109
–
20
.

8

Ellis
 
J
,
Groppelli
 
E
,
Doyle
 
R
, et al.  
Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial
.
Lancet HIV
 
2025
;
12
:
e691
–
700
.

9

Skipper
 
CP
,
Schleiss
 
MR
.
Cytomegalovirus viremia and advanced HIV disease: is there an argument for anti-CMV treatment?
 
Expert Rev Anti Infect Ther
 
2023
;
21
:
227
–
33
.

10

Sahin
 
SZ
,
Akalin
 
H
,
Ersoy
 
A
, et al.  
Invasive fungal infections in renal transplant recipients: epidemiology and risk factors
.
Mycopathologia
 
2015
;
180
:
43
–
50
.

11

Yong
 
MK
,
Ananda-Rajah
 
M
,
Cameron
 
PU
, et al.  
Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring
.
Biol Blood Marrow Transplant
 
2017
;
23
:
1961
–
7
.

12

Ota
 
Y
,
Kaneko
 
Y
,
Takeuchi
 
T
.
Association between mortality and cytomegalovirus reactivation during remission induction therapy in patients with rheumatic diseases
.
Clin Exp Rheumatol
 
2021
;
39
:
1324
–
30
.

13

Lowance
 
D
,
Neumayer
 
HH
,
Legendre
 
CM
, et al.  
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International valacyclovir cytomegalovirus prophylaxis transplantation study group
.
N Engl J Med
 
1999
;
340
:
1462
–
70
.

14

Boulware
 
DR
,
Rolfes
 
MA
,
Rajasingham
 
R
, et al.  
Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast
.
Emerg Infect Dis
 
2014
;
20
:
45
–
53
.

15

Dyal
 
J
,
Akampurira
 
A
,
Rhein
 
J
, et al.  
Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis
.
Med Mycol
 
2016
;
54
:
361
–
9
.

16

Boulware
 
DR
,
Meya
 
DB
,
Muzoora
 
C
, et al.  
Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis
.
N Engl J Med
 
2014
;
370
:
2487
–
98
.

17

Rhein
 
J
,
Huppler Hullsiek
 
K
,
Tugume
 
L
, et al.  
Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial
.
Lancet Infect Dis
 
2019
;
19
:
843
–
51
.

18

Boulware
 
DR
,
Atukunda
 
M
,
Kagimu
 
E
, et al.  
Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial
.
Clin Infect Dis
 
2023
;
77
:
1659
–
67
.

19

Ellis
 
J
,
Nsangi
 
L
,
Bangdiwala
 
A
, et al.  
Integrated management of cryptococcal meningitis and concurrent opportunistic infections to improve outcomes in advanced HIV disease: a randomised strategy trial
.
Wellcome Open Res
 
2024
;
9
:
14
.

20

Mugabi
 
T
,
Namombwe
 
S
,
Dai
 
B
, et al.  
Etiology and outcomes of meningitis among adults in three Ugandan referral hospitals, 2018–2023: a prospective cohort study in a high-HIV endemic setting
.
Am J Trop Med Hyg
 
2025
;
112
:
1273
–
9
.

21

Dollard
 
SC
,
Dreon
 
M
,
Hernandez-Alvarado
 
N
, et al.  
Sensitivity of dried blood spot testing for detection of congenital cytomegalovirus infection
.
JAMA Pediatr
 
2021
;
175
:e205441.

22

Levi
 
LI
,
Sharma
 
S
,
Schleiss
 
MR
, et al.  
Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy
.
AIDS (London, England)
 
2022
;
36
:
1265
.

23

1st WHO International Standard for Human Cytomegalovirus for Nucleic Acid Amplification Techniques. World Health Organization. NIBSC code: 09/162. Version 6.0. Dated 09/10/2014. https://nibsc.org/documents/ifu/09-162.pdf

24

Spector
 
SA
,
Wong
 
R
,
Hsia
 
K
,
Pilcher
 
M
,
Stempien
 
MJ
.
Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients
.
J Clin Invest
 
1998
;
101
:
497
–
502
.

25

Deayton
 
JR
,
Sabin
 
CA
,
Johnson
 
MA
,
Emery
 
VC
,
Wilson
 
P
,
Griffiths
 
PD
.
Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy
.
Lancet
 
2004
;
363
:
2116
–
21
.

26

Wohl
 
DA
,
Zeng
 
D
,
Stewart
 
P
, et al.  
Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies
.
J Acquir Immune Defic Syndr
 
2005
;
38
:
538
–
44
.

27

Fielding
 
K
,
Koba
 
A
,
Grant
 
AD
, et al.  
Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa
.
PLoS One
 
2011
;
6
:e25571.

28

Atalla
 
A
,
Garnica
 
M
,
Maiolino
 
A
,
Nucci
 
M
.
Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients
.
Transpl Infect Dis
 
2015
;
17
:
7
–
13
.

29

Chuleerarux
 
N
,
Nematollahi
 
S
,
Thongkam
 
A
, et al.  
The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis
.
Clin Microbiol Infect
 
2022
;
28
:
332
–
44
.

30

Fortún
 
J
,
Martín-Dávila
 
P
,
Moreno
 
S
, et al.  
Risk factors for invasive aspergillosis in liver transplant recipients
.
Liver Transpl
 
2002
;
8
:
1065
–
70
.

31

Rosenhagen
 
M
,
Feldhues
 
R
,
Schmidt
 
J
,
Hoppe-Tichy
 
T
,
Geiss
 
HK
.
A risk profile for invasive aspergillosis in liver transplant recipients
.
Infection
 
2009
;
37
:
313
–
9
.

32

Chevalier
 
MS
,
Daniels
 
GM
,
Johnson
 
DC
.
Binding of human cytomegalovirus US2 to major histocompatibility complex class I and II proteins is not sufficient for their degradation
.
J Virol
 
2002
;
76
:
8265
–
75
.

33

Frascaroli
 
G
,
Varani
 
S
,
Blankenhorn
 
N
, et al.  
Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor
.
J Immunol
 
2009
;
182
:
477
–
88
.

34

Peppa
 
D
.
Natural killer cells in human immunodeficiency virus-1 infection: spotlight on the impact of human cytomegalovirus
.
Front Immunol
 
2017
;
8
:
1322
.

35

Essa
 
S
,
Pacsa
 
A
,
Raghupathy
 
R
, et al.  
Low levels of Th1-type cytokines and increased levels of Th2-type cytokines in kidney transplant recipients with active cytomegalovirus infection
.
Transplant Proc
 
2009
;
41
:
1643
–
7
.

36

Hunt
 
PW
,
Martin
 
JN
,
Sinclair
 
E
, et al.  
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy
.
J Infect Dis
 
2011
;
203
:
1474
–
83
.

Author notes

Caleb P Skipper and Timothy Mugabi equal contribution.

Potential conflicts of interest. All authors: No reported conflicts.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].

Supplementary data

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Gift article access

Please create a link below to share with others. This will provide temporary access to this restricted article.

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period